Home > Insider Trading > Filing (0001144204-15-010744)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1001233	Sangamo Biosciences Inc	SGMO	Biological Products, (No Disgnostic Substances) (2836)	680359556

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes
1346824	Ra Capital Management, Llc	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes
1384859	Peter Kolchinsky	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116	No	No	No	Yes

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-07-17	19,200	$9.79	3,645,703	No	4	P	Direct
Common Stock	Disposition	2013-07-17	19,200	$10.24	3,626,503	No	4	S	Direct
Common Stock	Disposition	2013-07-17	29,070	$10.21	3,626,503	No	4	S	Direct
Common Stock	Disposition	2013-07-18	74,035	$10.02	3,626,503	No	4	S	Direct
Common Stock	Disposition	2013-07-19	23,040	$9.77	3,603,463	No	4	S	Direct
Common Stock	Disposition	2013-07-19	76,800	$9.85	3,603,463	No	4	S	Direct
Common Stock	Disposition	2013-07-19	4,532	$9.85	3,603,463	No	4	S	Direct
Common Stock	Disposition	2013-07-19	105,522	$9.85	3,603,463	No	4	S	Direct
Common Stock	Disposition	2013-07-22	76,801	$9.56	3,526,662	No	4	S	Direct
Common Stock	Disposition	2013-07-22	11,520	$9.57	3,515,142	No	4	S	Direct
Common Stock	Disposition	2013-07-22	23,042	$9.60	3,492,100	No	4	S	Direct
Common Stock	Disposition	2013-07-23	5,012	$9.37	3,487,088	No	4	S	Direct
Common Stock	Disposition	2013-07-25	4,071	$9.51	3,483,017	No	4	S	Direct
Common Stock	Disposition	2013-07-25	191,999	$9.50	3,291,018	No	4	S	Direct
Common Stock	Disposition	2013-07-25	19,200	$10.00	3,271,818	No	4	S	Direct
Common Stock	Disposition	2013-07-25	76,800	$9.91	3,195,018	No	4	S	Direct
Common Stock	Disposition	2013-07-25	76,800	$10.00	3,118,218	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The reported securities are owned by RA Capital Healthcare Fund, L.P. (the "Fund"). RA Capital Management, LLC (the "Adviser") is the general partner of the Fund, and Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively, and therefore disclaim any obligation to report ownership of the reported securities other than on behalf of the Fund. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Mr. Kolchinsky is or was, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of any of the securities reported herein. The number of shares reported in Column 5 of Table I reflects the number of shares beneficially owned by the Fund as of the time of the last transaction reported herein.
The Fund borrowed shares for delivery against the sale.
On June 26, 2013, the Fund became a beneficial owner of more than ten percent of the outstanding shares the issuer's common stock and therefore became subject to Section 16 of the Securities Exchange Act of 1934. On July 25, 2013, the Fund ceased to be a beneficial owner of more than ten percent of the outstanding shares of the issuer's common stock and ceased to be subject to Section 16.